SCHEMBL333040

SCHEMBL333040

C#CCNCCCCCCCCCCCC

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SAT1 P21673 1/20 0.60
TSHR P16473 3/20 0.57
ALDH1A1 P00352 1/20 0.57
EPHX1 P07099 4/20 0.46
ADH1B P00325 1/20 0.46
ADH1C P00326 1/20 0.46
ADH1A P07327 1/20 0.46
ADH4 P08319 1/20 0.46
ADH7 P40394 1/20 0.46
S1PR2 O95136 5/20 0.42
S1PR4 O95977 5/20 0.42
S1PR1 P21453 5/20 0.42
S1PR3 Q99500 5/20 0.42
S1PR5 Q9H228 1/20 0.42
THRB P10828 1/20 0.40
SMN1; SMN2 Q16637 3/20 0.39
LMNA P02545 2/20 0.39
RAB9A P51151 2/20 0.39
HTT P42858 2/20 0.39
MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL332965 1.00 SAT1 (0.60) SAT1TSHRALDH1A1EPHX1ADH1B
SCHEMBL4424094 1.00 SAT1 (0.60) SAT1TSHRALDH1A1EPHX1ADH1B
SCHEMBL27896724 1.00 SAT1 (0.60) SAT1TSHRALDH1A1EPHX1ADH1B
SCHEMBL6832121 1.00 SAT1 (0.60) SAT1TSHRALDH1A1EPHX1ADH1B
SCHEMBL332496 1.00 SAT1 (0.60) SAT1TSHRALDH1A1EPHX1ADH1B
SCHEMBL333465 1.00 SAT1 (0.60) SAT1TSHRALDH1A1EPHX1ADH1B
SCHEMBL332482 1.00 SAT1 (0.60) SAT1TSHRALDH1A1EPHX1ADH1B
SCHEMBL333304 1.00 SAT1 (0.60) SAT1TSHRALDH1A1EPHX1ADH1B
SCHEMBL9348906 1.00 SAT1 (0.60) SAT1TSHRALDH1A1EPHX1ADH1B
Hydrochloric Acid SCHEMBL25309116 0.98 SAT1 (0.58) SAT1TSHRALDH1A1EPHX1ADH1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2203150-B1 PERSONAL CARE COMPOSITIONS COMPRISING UNDECYL SULFATES PROCTER & GAMBLE (US) 2016-06-01 EP claimed
EP-2531181-A1 EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF Pharma Two B Ltd. (IL) 2012-12-12 EP claimed
US-20120301542-A1 EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF PHARMA TWO B LTD. (IL) 2012-11-29 US claimed
CN-102791258-A Extended release formulations of rasagiline and uses thereof PHARMA TWO B LTD 2012-11-21 CN claimed
WO-2011095973-A1 EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF PHARMA TWO B LTD. (IL) 2011-08-11 WO claimed
EP-1686973-A4 COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES TECHNION RES & DEV FOUNDATION (IL) 2009-03-25 EP claimed
EP-1942881-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE Technion Research and Development of Foundation, Ltd. (IL) 2008-07-16 EP claimed
US-20080090915-A1 METHOD FOR PREVENTING OR ATTENUATING ANTHRACYCLINE-INDUCED CARDIOTOXICITY TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2008-04-17 US claimed
WO-2007039909-A2 COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2007-04-12 WO claimed
US-20060287401-A1 Methods for treatment of cardiovascular disorders and diseases TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2006-12-21 US claimed
EP-1686973-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) 2006-08-09 EP claimed
US-20050171210-A1 Compositions and methods for treatment of cardiovascular disorders and diseases TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) 2005-08-04 US claimed
WO-2005051371-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) 2005-06-09 WO claimed
EP-0996612-B1 ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS UNIV SASKATCHEWAN (CA) 2003-04-09 EP claimed
US-6251950-B1 ADMINISTERING TO THE PATIENT AN ALIPHATIC-PROPARGYLAMINE OR SALT FOR THE TREATMENT OF ACUTE AND CHRONIC DISEASES IN WHICH CELL DEATH OCCURS BY APOPTOSIS OR FOR THE TREATMENT OF PREMATURE DEGENERATION OF CELLS IN MAMMALS UNIVERSITY OF SASKATCHEWAN (CA) 2001-06-26 US claimed
EP-0996612-A2 ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS University of Saskatchewan Technologies Inc. (CA) 2000-05-03 EP claimed
WO-1999003817-A2 ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. (CA) 1999-01-28 WO claimed
EP-3517103-A1 EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF Pharma Two B Ltd. (IL) 2019-07-31 EP disclosed
WO-1999003817-A2 ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. (CA) 1999-01-28 WO disclosed
US-5840979-A USEFUL IN THE TREATMENT AND PREVENTION OF DISEASES IN WHICH CELL DEATH OCCURS BY APOPTOSIS UNIVERSITY OF SASKATCHEWAN (CA) 1998-11-24 US disclosed